경남제약

053950KOSDAQSector: Pharma & Biotech

₩1,539▲ 1.12%Market cap ₩24.1BAs of Jul 21, 2026 close · updated once daily

Grade B52.2 ptsTop 49% of 2,523 stocks

Financial strength

50.5

Price attractiveness

54.1

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

ⓘ Growth momentum not rated — will be included automatically as data accumulates

Financial strength

50.5

How much debt does it carry relative to equity?

Debt-to-equity ratio

43.7%

✓ Above median · Top 40.4% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

171.8%

✗ Below median · Top 52.2% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-3.1%

✗ Below median · Top 51.6% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-8.3%

✗ Below median · Top 53.9% in sector

Sector median -4.5%

Source filing: annual report (separate) — view original ↗

Price attractiveness

54.1

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 90.9% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

0.22x

✓ Above median · Top 1% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15